Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

Stefan D. Anker1,2,3*, Javed Butler4, Gerasimos Filippatos5, Muhammad Shahzeb Khan4, João Pedro Ferreira6, Edimar Bocchi7, Michael Böhm8, Hans Pieter Brunner-La Rocca9, Dong-Ju Choi10, Vijay Chopra11, Eduardo Chuquiure12, Nadia Giannetti13, Juan Esteban Gomez-Mesa14, Stefan Janssens15, James L. Januzzi16, Jose R. Gonzalez-Juanatey17, Bela Merkely18, Stephen J. Nicholls19, Sergio V. Perrone20, Ileana L. Piña21, Piotr Ponikowski22, Michele Senni23, Marie-France Seronde24, David Sim25, Jindrich Spinar26, Iain Squire27, Stefano Taddei28, Hiroyuki Tsutsui29, Subodh Verma30, Dragos Vinereanu31, Jian Zhang32, Waheed Jamal33, Sven Schnaidt34, Janet M. Schnee35, Martina Brueckmann33,36, Stuart J. Pocock37, Faiez Zannad6, and Milton Packer38,39 for the EMPEROR-Preserved Trial Committees and Investigators

[1]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[2]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[3]  M. Vaduganathan,et al.  Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. , 2020, Circulation. Heart failure.

[4]  S. Heymans,et al.  Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial , 2020, European journal of heart failure.

[5]  G. Bakris,et al.  Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure , 2020, European journal of heart failure.

[6]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[7]  G. Filippatos,et al.  Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial , 2019, European journal of heart failure.

[8]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[9]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[10]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[11]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.

[12]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[13]  W. Paulus,et al.  Heart failure with preserved ejection fraction: uncertainties and dilemmas , 2015, European journal of heart failure.

[14]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[15]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[16]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[17]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[18]  G. Lamas,et al.  Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM , 2007, European journal of heart failure.

[19]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[20]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[21]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[22]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.